Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580
Debt
Debt-to-Equity Ratio0.02
Current Ratio15.40
Quick Ratio15.40
Price-To-Earnings
Trailing P/E Ratio-15.76
Forward P/E Ratio-11.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.43 million
Price / Sales125.83
Cash FlowN/A
Price / CashN/A
Book Value$14.55 per share
Price / Book4.23
Profitability
EPS (Most Recent Fiscal Year)($3.92)
Net Income$-148,110,000.00
Net Margins-1,068.27%
Return on Equity-37.00%
Return on Assets-31.48%
Miscellaneous
Employees149
Outstanding Shares43,840,000
Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions
What is Blueprint Medicines' stock symbol?
Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."
How were Blueprint Medicines' earnings last quarter?
Blueprint Medicines Corp (NASDAQ:BPMC) issued its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.06) by $0.23. The biotechnology company earned $0.95 million during the quarter, compared to analysts' expectations of $2.82 million. Blueprint Medicines had a negative return on equity of 37.00% and a negative net margin of 1,068.27%. The company's quarterly revenue was down 83.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.84) EPS. View Blueprint Medicines' Earnings History.
When is Blueprint Medicines' next earnings date?
What price target have analysts set for BPMC?
10 Wall Street analysts have issued twelve-month target prices for Blueprint Medicines' stock. Their predictions range from $56.00 to $106.00. On average, they expect Blueprint Medicines' share price to reach $87.1111 in the next twelve months. View Analyst Ratings for Blueprint Medicines.
What are Wall Street analysts saying about Blueprint Medicines stock?
Here are some recent quotes from research analysts about Blueprint Medicines stock:
- 1. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (5/7/2018)
- 2. Cowen Inc analysts commented, "We maintain our BUY rating following the Q3/17 results. Histogenics reported zero revenue and a diluted net loss of $5.1M, compared to CG/ consensus of $6.5M/$6.3M net loss, and LPS of $(0.23), compared with CG/consensus estimate of $(0.29)/$(0.28). As anticipated, the Q3 call was largely uneventful as Histogenics awaits one-year data from the NeoCart Phase 3 clinical trial. Management noted that 65% of patients are now at the one-year mark and reiterated their expectation for one-year data to be announced in Q3/18." (11/10/2017)
Who are some of Blueprint Medicines' key competitors?
Some companies that are related to Blueprint Medicines include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), BeiGene (BGNE), Genmab A/S (GNMSF), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO) and FibroGen (FGEN).
Who are Blueprint Medicines' key executives?
Blueprint Medicines' management team includes the folowing people:
- Mr. Daniel S. Lynch, Exec. Chairman (Age 60)
- Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 47)
- Mr. Alexis Borisy, Co-Founder & Director (Age 46)
- Dr. Marion Dorsch Ph.D., Chief Scientific Officer (Age 53)
- Ms. Tracey L. Mccain Esq., Chief Legal Officer and Exec. VP (Age 50)
When did Blueprint Medicines IPO?
(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has Blueprint Medicines been receiving favorable news coverage?
Media stories about BPMC stock have been trending positive recently, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Blueprint Medicines earned a daily sentiment score of 0.36 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.50 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Blueprint Medicines' major shareholders?
Blueprint Medicines' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.43%), OppenheimerFunds Inc. (3.68%), Lord Abbett & CO. LLC (3.63%), BVF Inc. IL (1.50%), Opaleye Management Inc. (1.37%) and Northern Trust Corp (1.13%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Kevin P Starr, Marion Dorsch, Mark J Levin, Nicholas Lydon and Rock Ventures Ii LP Third. View Institutional Ownership Trends for Blueprint Medicines.
Which major investors are selling Blueprint Medicines stock?
BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Opaleye Management Inc., BVF Inc. IL, Sei Investments Co., Spark Investment Management LLC, Sandia Holdings LLC, OppenheimerFunds Inc. and Point72 Asset Management L.P.. Company insiders that have sold Blueprint Medicines company stock in the last year include Anthony L Boral, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.
Which major investors are buying Blueprint Medicines stock?
BPMC stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Alkeon Capital Management LLC, Federated Investors Inc. PA, Millennium Management LLC, Dimensional Fund Advisors LP, American Century Companies Inc., UBS Group AG and Bollard Group LLC. View Insider Buying and Selling for Blueprint Medicines.
How do I buy shares of Blueprint Medicines?
Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Blueprint Medicines' stock price today?
One share of BPMC stock can currently be purchased for approximately $61.51.
How big of a company is Blueprint Medicines?
Blueprint Medicines has a market capitalization of $2.91 billion and generates $21.43 million in revenue each year. The biotechnology company earns $-148,110,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Blueprint Medicines employs 149 workers across the globe.
How can I contact Blueprint Medicines?
Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]
MarketBeat Community Rating for Blueprint Medicines (BPMC)
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
